Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Sales reflect continued strong growth in oncology and vaccines
Open a printable version of this pageEmail the URL of this page to a friend
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Submission based on results from pivotal phase III trial showing all primary endpoints met
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Subscribe To Our Newsletter & Stay Updated
